Myriad Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Uncover the strategic positioning of this company's product portfolio with our insightful BCG Matrix preview. See how its offerings stack up as Stars, Cash Cows, Dogs, or Question Marks, and understand the implications for future growth. Purchase the full BCG Matrix for a comprehensive breakdown, data-driven recommendations, and a clear roadmap to optimize your investments and product strategy.
Stars
MyRisk with RiskScore for Oncology
Myriad's MyRisk with RiskScore is a standout performer in the oncology market, showcasing robust leadership in hereditary cancer testing. This test is a significant contributor to Myriad's overall success.
The demand for MyRisk with RiskScore in oncology is clearly on the rise. For the second quarter of 2025, testing volume saw a healthy 14% increase compared to the same period in 2024. This growth highlights its strong market penetration and the increasing need for such diagnostic tools.
Precise MRD Test Development
The Precise Molecular Residual Disease (MRD) test is a standout performer for Myriad, addressing a rapidly expanding market. This segment is expected to grow from $1.87 billion in 2024 to $3.54 billion by 2030, showcasing significant upside potential.
Myriad's Precise MRD test is designed for ultra-sensitivity and can be applied across various cancer types, positioning it strongly to gain considerable market share in this burgeoning field.
The unveiling of new clinical data in May 2025 will further underscore the innovative nature and high potential of this critical diagnostic tool.
Overall Oncology Hereditary Cancer Segment
Myriad's hereditary cancer testing segment, a cornerstone of its oncology offerings, demonstrated impressive growth. In the second quarter of 2025, this segment, which includes key products like MyRisk and BRACAnalysis, saw its revenue climb by 9% compared to the same period in the prior year.
This strong performance underscores Myriad's significant market share within the rapidly expanding precision oncology landscape. The company's strategic commitment to the Cancer Care Continuum further solidifies its position and ongoing investment in this critical area of healthcare.
Strategic Investments in AI-Enabled Diagnostics
Myriad's strategic investments in AI-enabled diagnostics, such as its collaboration with PATHOMIQ for prostate cancer detection, position it to capture growth in the burgeoning oncology market. These initiatives, though potentially in their nascent stages, target high-potential areas within cancer diagnostics. By focusing on these advanced technologies, Myriad aims to solidify its future market leadership and ensure continued expansion.
These AI-driven diagnostic tools are not just about innovation; they're about tangible improvements in patient care and market differentiation. For example, AI in pathology can significantly speed up diagnosis and improve accuracy, a critical factor in cancer treatment. The global AI in healthcare market was valued at approximately $15.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 37% from 2024 to 2030, indicating a substantial opportunity for companies like Myriad investing in this space.
- AI in Diagnostics: Myriad's partnership with PATHOMIQ for AI-powered prostate cancer diagnostics.
- Market Potential: Targeting high-growth oncology segments with advanced diagnostic solutions.
- Future Growth: Investments aimed at securing future market leadership and sustained revenue streams.
- Industry Growth: The AI in healthcare market is a rapidly expanding sector, projected for significant growth.
Expansion of Hereditary Cancer Testing for Affected Individuals
Myriad Genetics is strategically expanding its hereditary cancer testing services, particularly for individuals already diagnosed with cancer. This focus goes beyond their established MyRisk test with RiskScore, targeting the oncology patient population where genetic information directly influences treatment pathways and therapeutic choices.
This concentrated effort leverages Myriad's existing strong market position in hereditary cancer testing. By deepening their penetration within the affected patient segment, they aim to become an indispensable partner in oncology care, where genetic insights are increasingly critical for personalized medicine.
The company's sustained investment in this area is a key driver for maintaining its high market share and achieving continued growth. This strategic direction is supported by the growing understanding of how hereditary cancer predispositions impact treatment efficacy and patient outcomes.
- Market Penetration: Myriad aims to increase its share within the oncology patient population by offering advanced hereditary cancer testing.
- Treatment Guidance: Genetic insights from these tests are vital for oncologists in making informed treatment decisions for cancer patients.
- Investment Focus: Continued investment in this segment is expected to solidify Myriad's leadership and drive future revenue growth.
- Oncology Integration: The expansion aligns with the broader trend of integrating genetic testing into routine cancer care protocols.
Myriad's High-Growth Products Drive Oncology Advancements
Myriad's Stars, representing its most promising and high-growth products, include MyRisk with RiskScore and the Precise Molecular Residual Disease (MRD) test. These products are at the forefront of precision oncology, addressing critical needs in cancer diagnosis and management.
The hereditary cancer testing segment, featuring MyRisk, saw a 9% revenue increase in Q2 2025 year-over-year, demonstrating strong market traction. The Precise MRD test is positioned to capitalize on the expanding MRD market, projected to reach $3.54 billion by 2030 from $1.87 billion in 2024.
Myriad's strategic focus on AI-enabled diagnostics further bolsters its Star products, with AI in healthcare market growth anticipated at over 37% CAGR from 2024-2030. These investments are crucial for maintaining market leadership and driving future revenue.
| Product | Market Segment | Q2 2025 Growth (YoY) | Market Size (2024) | Projected Market Growth (CAGR) |
|---|---|---|---|---|
| MyRisk with RiskScore | Hereditary Cancer Testing | 9% | N/A | N/A |
| Precise MRD Test | Molecular Residual Disease | N/A | $1.87 billion | 37%+ (AI in Healthcare Market) |
What is included in the product
Detailed Word Document
The Myriad BCG Matrix offers a strategic overview of a company's product portfolio, categorizing units into Stars, Cash Cows, Question Marks, and Dogs.
This framework guides decisions on investment, divestment, and resource allocation for optimal business growth.
Customizable Excel Spreadsheet
Clear visual of your portfolio's strengths and weaknesses.
Cash Cows
Established Prenatal Testing Portfolio
Myriad's established prenatal testing portfolio, featuring products like Foresight and Prequel, continues to be a significant revenue driver for the company. This segment holds a strong market position in a mature, yet stable, industry.
Despite a temporary dip in order volume in Q2 2025 attributed to a system issue, the prenatal testing business demonstrated resilience. Revenue saw a 7% year-over-year increase in Q2 2025, following an impressive 11% growth in Q1 2025, underscoring its cash cow status.
Core Hereditary Cancer Testing for Unaffected Population
Myriad's core hereditary cancer testing for the unaffected population acts as a classic cash cow. These established tests, designed for risk assessment, provide a stable and foundational revenue stream for the company.
While the growth for these offerings is more measured, projected at 1-3% volume and revenue growth in Q2 2025, they command a significant market share. This strong market position allows them to generate consistent cash flow, requiring minimal additional investment to maintain their performance.
High Gross Margins from Lab Efficiencies
Myriad's commitment to operational excellence has translated into significant laboratory efficiencies, a key driver for its robust financial performance. This focus on streamlining processes allows the company to achieve impressive adjusted gross margins, which stood at 71.5% in the second quarter of 2025.
These high margins on its established product lines clearly demonstrate their status as cash cows. The company is effectively leveraging its operational strengths to generate substantial profits from these mature offerings, allowing it to maximize returns from existing investments.
BRACAnalysis and BRACAnalysis CDx
BRACAnalysis and BRACAnalysis CDx represent Myriad Genetics' established "cash cows" within the BCG matrix framework. These pioneering tests for hereditary cancer have carved out a significant market share, benefiting from strong brand recognition built over years of reliable performance.
While these products may be considered in a more mature stage, they consistently generate substantial and dependable cash flow for Myriad. This financial stability is crucial, underpinning the company's ability to invest in research and development for newer, potentially high-growth products.
- Market Leadership: BRACAnalysis was a first-of-its-kind test, establishing Myriad as a leader in hereditary cancer diagnostics.
- Consistent Revenue: These tests continue to be a primary revenue driver, contributing significantly to Myriad's financial health.
- Foundation of Business: They form the bedrock of Myriad's diagnostic portfolio, supporting innovation in other areas.
- Brand Loyalty: Decades of clinical use have fostered trust and loyalty among healthcare providers and patients.
Stable Revenue from Women's Health Segment
Myriad's Women's Health segment, encompassing prenatal and hereditary cancer tests for individuals without a current diagnosis, is a significant contributor to its financial stability. In the second quarter of 2025, this business unit generated an impressive $89.8 million in revenue.
This segment is characterized by its consistent performance and enduring demand, making it a dependable source of cash flow for Myriad. The predictable nature of these services underpins its classification as a Cash Cow within the BCG Matrix.
- Women's Health Revenue (Q2 2025): $89.8 million
- Key Offerings: Prenatal tests, hereditary cancer tests for unaffected individuals
- Performance Characteristic: Stable revenue and consistent demand
- BCG Matrix Classification: Cash Cow
Cash Cows: Stable Revenue Streams
Myriad's established hereditary cancer testing, particularly BRACAnalysis and BRACAnalysis CDx, are prime examples of Cash Cows. These pioneering tests have secured a dominant market share, fueled by decades of clinical use and strong brand recognition.
These mature offerings consistently generate substantial, dependable cash flow, which is crucial for funding Myriad's research and development in newer, high-growth areas. Their stable revenue stream, despite more measured growth projections, highlights their foundational importance to the company's financial health.
The Women's Health segment, including prenatal and hereditary cancer tests for unaffected individuals, also functions as a Cash Cow. This segment posted $89.8 million in revenue in Q2 2025, demonstrating stable performance and consistent demand.
The company's operational efficiencies, contributing to a 71.5% adjusted gross margin in Q2 2025, further bolster the profitability of these established product lines, solidifying their Cash Cow status.
| Product/Segment | BCG Classification | Q2 2025 Revenue | Projected Growth (2025) | Key Characteristic |
|---|---|---|---|---|
| BRACAnalysis/BRACAnalysis CDx | Cash Cow | N/A (Part of Women's Health) | 1-3% | Market leader, consistent cash flow |
| Prenatal Testing (Foresight, Prequel) | Cash Cow | N/A (Part of Women's Health) | N/A | Stable, resilient revenue driver |
| Women's Health (Overall) | Cash Cow | $89.8 million | N/A | Dependable, predictable cash flow |
What Youāre Viewing Is Included
Myriad BCG Matrix
The preview you're viewing is the identical, fully functional Myriad BCG Matrix document you'll receive upon purchase. This means no watermarks, no demo content, and no hidden surprises ā just the complete, professionally formatted strategic tool ready for immediate implementation. You can confidently assess its value and utility, knowing the purchased version will be exactly the same, enabling seamless integration into your business planning and decision-making processes.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Myriad Boston Consulting Group Matrix
Myriad Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Uncover the strategic positioning of this company's product portfolio with our insightful BCG Matrix preview. See how its offerings stack up as Stars, Cash Cows, Dogs, or Question Marks, and understand the implications for future growth. Purchase the full BCG Matrix for a comprehensive breakdown, data-driven recommendations, and a clear roadmap to optimize your investments and product strategy.
Stars
MyRisk with RiskScore for Oncology
Myriad's MyRisk with RiskScore is a standout performer in the oncology market, showcasing robust leadership in hereditary cancer testing. This test is a significant contributor to Myriad's overall success.
The demand for MyRisk with RiskScore in oncology is clearly on the rise. For the second quarter of 2025, testing volume saw a healthy 14% increase compared to the same period in 2024. This growth highlights its strong market penetration and the increasing need for such diagnostic tools.
Precise MRD Test Development
The Precise Molecular Residual Disease (MRD) test is a standout performer for Myriad, addressing a rapidly expanding market. This segment is expected to grow from $1.87 billion in 2024 to $3.54 billion by 2030, showcasing significant upside potential.
Myriad's Precise MRD test is designed for ultra-sensitivity and can be applied across various cancer types, positioning it strongly to gain considerable market share in this burgeoning field.
The unveiling of new clinical data in May 2025 will further underscore the innovative nature and high potential of this critical diagnostic tool.
Overall Oncology Hereditary Cancer Segment
Myriad's hereditary cancer testing segment, a cornerstone of its oncology offerings, demonstrated impressive growth. In the second quarter of 2025, this segment, which includes key products like MyRisk and BRACAnalysis, saw its revenue climb by 9% compared to the same period in the prior year.
This strong performance underscores Myriad's significant market share within the rapidly expanding precision oncology landscape. The company's strategic commitment to the Cancer Care Continuum further solidifies its position and ongoing investment in this critical area of healthcare.
Strategic Investments in AI-Enabled Diagnostics
Myriad's strategic investments in AI-enabled diagnostics, such as its collaboration with PATHOMIQ for prostate cancer detection, position it to capture growth in the burgeoning oncology market. These initiatives, though potentially in their nascent stages, target high-potential areas within cancer diagnostics. By focusing on these advanced technologies, Myriad aims to solidify its future market leadership and ensure continued expansion.
These AI-driven diagnostic tools are not just about innovation; they're about tangible improvements in patient care and market differentiation. For example, AI in pathology can significantly speed up diagnosis and improve accuracy, a critical factor in cancer treatment. The global AI in healthcare market was valued at approximately $15.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 37% from 2024 to 2030, indicating a substantial opportunity for companies like Myriad investing in this space.
- AI in Diagnostics: Myriad's partnership with PATHOMIQ for AI-powered prostate cancer diagnostics.
- Market Potential: Targeting high-growth oncology segments with advanced diagnostic solutions.
- Future Growth: Investments aimed at securing future market leadership and sustained revenue streams.
- Industry Growth: The AI in healthcare market is a rapidly expanding sector, projected for significant growth.
Expansion of Hereditary Cancer Testing for Affected Individuals
Myriad Genetics is strategically expanding its hereditary cancer testing services, particularly for individuals already diagnosed with cancer. This focus goes beyond their established MyRisk test with RiskScore, targeting the oncology patient population where genetic information directly influences treatment pathways and therapeutic choices.
This concentrated effort leverages Myriad's existing strong market position in hereditary cancer testing. By deepening their penetration within the affected patient segment, they aim to become an indispensable partner in oncology care, where genetic insights are increasingly critical for personalized medicine.
The company's sustained investment in this area is a key driver for maintaining its high market share and achieving continued growth. This strategic direction is supported by the growing understanding of how hereditary cancer predispositions impact treatment efficacy and patient outcomes.
- Market Penetration: Myriad aims to increase its share within the oncology patient population by offering advanced hereditary cancer testing.
- Treatment Guidance: Genetic insights from these tests are vital for oncologists in making informed treatment decisions for cancer patients.
- Investment Focus: Continued investment in this segment is expected to solidify Myriad's leadership and drive future revenue growth.
- Oncology Integration: The expansion aligns with the broader trend of integrating genetic testing into routine cancer care protocols.
Myriad's High-Growth Products Drive Oncology Advancements
Myriad's Stars, representing its most promising and high-growth products, include MyRisk with RiskScore and the Precise Molecular Residual Disease (MRD) test. These products are at the forefront of precision oncology, addressing critical needs in cancer diagnosis and management.
The hereditary cancer testing segment, featuring MyRisk, saw a 9% revenue increase in Q2 2025 year-over-year, demonstrating strong market traction. The Precise MRD test is positioned to capitalize on the expanding MRD market, projected to reach $3.54 billion by 2030 from $1.87 billion in 2024.
Myriad's strategic focus on AI-enabled diagnostics further bolsters its Star products, with AI in healthcare market growth anticipated at over 37% CAGR from 2024-2030. These investments are crucial for maintaining market leadership and driving future revenue.
| Product | Market Segment | Q2 2025 Growth (YoY) | Market Size (2024) | Projected Market Growth (CAGR) |
|---|---|---|---|---|
| MyRisk with RiskScore | Hereditary Cancer Testing | 9% | N/A | N/A |
| Precise MRD Test | Molecular Residual Disease | N/A | $1.87 billion | 37%+ (AI in Healthcare Market) |
What is included in the product
Detailed Word Document
The Myriad BCG Matrix offers a strategic overview of a company's product portfolio, categorizing units into Stars, Cash Cows, Question Marks, and Dogs.
This framework guides decisions on investment, divestment, and resource allocation for optimal business growth.
Customizable Excel Spreadsheet
Clear visual of your portfolio's strengths and weaknesses.
Cash Cows
Established Prenatal Testing Portfolio
Myriad's established prenatal testing portfolio, featuring products like Foresight and Prequel, continues to be a significant revenue driver for the company. This segment holds a strong market position in a mature, yet stable, industry.
Despite a temporary dip in order volume in Q2 2025 attributed to a system issue, the prenatal testing business demonstrated resilience. Revenue saw a 7% year-over-year increase in Q2 2025, following an impressive 11% growth in Q1 2025, underscoring its cash cow status.
Core Hereditary Cancer Testing for Unaffected Population
Myriad's core hereditary cancer testing for the unaffected population acts as a classic cash cow. These established tests, designed for risk assessment, provide a stable and foundational revenue stream for the company.
While the growth for these offerings is more measured, projected at 1-3% volume and revenue growth in Q2 2025, they command a significant market share. This strong market position allows them to generate consistent cash flow, requiring minimal additional investment to maintain their performance.
High Gross Margins from Lab Efficiencies
Myriad's commitment to operational excellence has translated into significant laboratory efficiencies, a key driver for its robust financial performance. This focus on streamlining processes allows the company to achieve impressive adjusted gross margins, which stood at 71.5% in the second quarter of 2025.
These high margins on its established product lines clearly demonstrate their status as cash cows. The company is effectively leveraging its operational strengths to generate substantial profits from these mature offerings, allowing it to maximize returns from existing investments.
BRACAnalysis and BRACAnalysis CDx
BRACAnalysis and BRACAnalysis CDx represent Myriad Genetics' established "cash cows" within the BCG matrix framework. These pioneering tests for hereditary cancer have carved out a significant market share, benefiting from strong brand recognition built over years of reliable performance.
While these products may be considered in a more mature stage, they consistently generate substantial and dependable cash flow for Myriad. This financial stability is crucial, underpinning the company's ability to invest in research and development for newer, potentially high-growth products.
- Market Leadership: BRACAnalysis was a first-of-its-kind test, establishing Myriad as a leader in hereditary cancer diagnostics.
- Consistent Revenue: These tests continue to be a primary revenue driver, contributing significantly to Myriad's financial health.
- Foundation of Business: They form the bedrock of Myriad's diagnostic portfolio, supporting innovation in other areas.
- Brand Loyalty: Decades of clinical use have fostered trust and loyalty among healthcare providers and patients.
Stable Revenue from Women's Health Segment
Myriad's Women's Health segment, encompassing prenatal and hereditary cancer tests for individuals without a current diagnosis, is a significant contributor to its financial stability. In the second quarter of 2025, this business unit generated an impressive $89.8 million in revenue.
This segment is characterized by its consistent performance and enduring demand, making it a dependable source of cash flow for Myriad. The predictable nature of these services underpins its classification as a Cash Cow within the BCG Matrix.
- Women's Health Revenue (Q2 2025): $89.8 million
- Key Offerings: Prenatal tests, hereditary cancer tests for unaffected individuals
- Performance Characteristic: Stable revenue and consistent demand
- BCG Matrix Classification: Cash Cow
Cash Cows: Stable Revenue Streams
Myriad's established hereditary cancer testing, particularly BRACAnalysis and BRACAnalysis CDx, are prime examples of Cash Cows. These pioneering tests have secured a dominant market share, fueled by decades of clinical use and strong brand recognition.
These mature offerings consistently generate substantial, dependable cash flow, which is crucial for funding Myriad's research and development in newer, high-growth areas. Their stable revenue stream, despite more measured growth projections, highlights their foundational importance to the company's financial health.
The Women's Health segment, including prenatal and hereditary cancer tests for unaffected individuals, also functions as a Cash Cow. This segment posted $89.8 million in revenue in Q2 2025, demonstrating stable performance and consistent demand.
The company's operational efficiencies, contributing to a 71.5% adjusted gross margin in Q2 2025, further bolster the profitability of these established product lines, solidifying their Cash Cow status.
| Product/Segment | BCG Classification | Q2 2025 Revenue | Projected Growth (2025) | Key Characteristic |
|---|---|---|---|---|
| BRACAnalysis/BRACAnalysis CDx | Cash Cow | N/A (Part of Women's Health) | 1-3% | Market leader, consistent cash flow |
| Prenatal Testing (Foresight, Prequel) | Cash Cow | N/A (Part of Women's Health) | N/A | Stable, resilient revenue driver |
| Women's Health (Overall) | Cash Cow | $89.8 million | N/A | Dependable, predictable cash flow |
What Youāre Viewing Is Included
Myriad BCG Matrix
The preview you're viewing is the identical, fully functional Myriad BCG Matrix document you'll receive upon purchase. This means no watermarks, no demo content, and no hidden surprises ā just the complete, professionally formatted strategic tool ready for immediate implementation. You can confidently assess its value and utility, knowing the purchased version will be exactly the same, enabling seamless integration into your business planning and decision-making processes.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Uncover the strategic positioning of this company's product portfolio with our insightful BCG Matrix preview. See how its offerings stack up as Stars, Cash Cows, Dogs, or Question Marks, and understand the implications for future growth. Purchase the full BCG Matrix for a comprehensive breakdown, data-driven recommendations, and a clear roadmap to optimize your investments and product strategy.
Stars
MyRisk with RiskScore for Oncology
Myriad's MyRisk with RiskScore is a standout performer in the oncology market, showcasing robust leadership in hereditary cancer testing. This test is a significant contributor to Myriad's overall success.
The demand for MyRisk with RiskScore in oncology is clearly on the rise. For the second quarter of 2025, testing volume saw a healthy 14% increase compared to the same period in 2024. This growth highlights its strong market penetration and the increasing need for such diagnostic tools.
Precise MRD Test Development
The Precise Molecular Residual Disease (MRD) test is a standout performer for Myriad, addressing a rapidly expanding market. This segment is expected to grow from $1.87 billion in 2024 to $3.54 billion by 2030, showcasing significant upside potential.
Myriad's Precise MRD test is designed for ultra-sensitivity and can be applied across various cancer types, positioning it strongly to gain considerable market share in this burgeoning field.
The unveiling of new clinical data in May 2025 will further underscore the innovative nature and high potential of this critical diagnostic tool.
Overall Oncology Hereditary Cancer Segment
Myriad's hereditary cancer testing segment, a cornerstone of its oncology offerings, demonstrated impressive growth. In the second quarter of 2025, this segment, which includes key products like MyRisk and BRACAnalysis, saw its revenue climb by 9% compared to the same period in the prior year.
This strong performance underscores Myriad's significant market share within the rapidly expanding precision oncology landscape. The company's strategic commitment to the Cancer Care Continuum further solidifies its position and ongoing investment in this critical area of healthcare.
Strategic Investments in AI-Enabled Diagnostics
Myriad's strategic investments in AI-enabled diagnostics, such as its collaboration with PATHOMIQ for prostate cancer detection, position it to capture growth in the burgeoning oncology market. These initiatives, though potentially in their nascent stages, target high-potential areas within cancer diagnostics. By focusing on these advanced technologies, Myriad aims to solidify its future market leadership and ensure continued expansion.
These AI-driven diagnostic tools are not just about innovation; they're about tangible improvements in patient care and market differentiation. For example, AI in pathology can significantly speed up diagnosis and improve accuracy, a critical factor in cancer treatment. The global AI in healthcare market was valued at approximately $15.4 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of over 37% from 2024 to 2030, indicating a substantial opportunity for companies like Myriad investing in this space.
- AI in Diagnostics: Myriad's partnership with PATHOMIQ for AI-powered prostate cancer diagnostics.
- Market Potential: Targeting high-growth oncology segments with advanced diagnostic solutions.
- Future Growth: Investments aimed at securing future market leadership and sustained revenue streams.
- Industry Growth: The AI in healthcare market is a rapidly expanding sector, projected for significant growth.
Expansion of Hereditary Cancer Testing for Affected Individuals
Myriad Genetics is strategically expanding its hereditary cancer testing services, particularly for individuals already diagnosed with cancer. This focus goes beyond their established MyRisk test with RiskScore, targeting the oncology patient population where genetic information directly influences treatment pathways and therapeutic choices.
This concentrated effort leverages Myriad's existing strong market position in hereditary cancer testing. By deepening their penetration within the affected patient segment, they aim to become an indispensable partner in oncology care, where genetic insights are increasingly critical for personalized medicine.
The company's sustained investment in this area is a key driver for maintaining its high market share and achieving continued growth. This strategic direction is supported by the growing understanding of how hereditary cancer predispositions impact treatment efficacy and patient outcomes.
- Market Penetration: Myriad aims to increase its share within the oncology patient population by offering advanced hereditary cancer testing.
- Treatment Guidance: Genetic insights from these tests are vital for oncologists in making informed treatment decisions for cancer patients.
- Investment Focus: Continued investment in this segment is expected to solidify Myriad's leadership and drive future revenue growth.
- Oncology Integration: The expansion aligns with the broader trend of integrating genetic testing into routine cancer care protocols.
Myriad's High-Growth Products Drive Oncology Advancements
Myriad's Stars, representing its most promising and high-growth products, include MyRisk with RiskScore and the Precise Molecular Residual Disease (MRD) test. These products are at the forefront of precision oncology, addressing critical needs in cancer diagnosis and management.
The hereditary cancer testing segment, featuring MyRisk, saw a 9% revenue increase in Q2 2025 year-over-year, demonstrating strong market traction. The Precise MRD test is positioned to capitalize on the expanding MRD market, projected to reach $3.54 billion by 2030 from $1.87 billion in 2024.
Myriad's strategic focus on AI-enabled diagnostics further bolsters its Star products, with AI in healthcare market growth anticipated at over 37% CAGR from 2024-2030. These investments are crucial for maintaining market leadership and driving future revenue.
| Product | Market Segment | Q2 2025 Growth (YoY) | Market Size (2024) | Projected Market Growth (CAGR) |
|---|---|---|---|---|
| MyRisk with RiskScore | Hereditary Cancer Testing | 9% | N/A | N/A |
| Precise MRD Test | Molecular Residual Disease | N/A | $1.87 billion | 37%+ (AI in Healthcare Market) |
What is included in the product
Detailed Word Document
The Myriad BCG Matrix offers a strategic overview of a company's product portfolio, categorizing units into Stars, Cash Cows, Question Marks, and Dogs.
This framework guides decisions on investment, divestment, and resource allocation for optimal business growth.
Customizable Excel Spreadsheet
Clear visual of your portfolio's strengths and weaknesses.
Cash Cows
Established Prenatal Testing Portfolio
Myriad's established prenatal testing portfolio, featuring products like Foresight and Prequel, continues to be a significant revenue driver for the company. This segment holds a strong market position in a mature, yet stable, industry.
Despite a temporary dip in order volume in Q2 2025 attributed to a system issue, the prenatal testing business demonstrated resilience. Revenue saw a 7% year-over-year increase in Q2 2025, following an impressive 11% growth in Q1 2025, underscoring its cash cow status.
Core Hereditary Cancer Testing for Unaffected Population
Myriad's core hereditary cancer testing for the unaffected population acts as a classic cash cow. These established tests, designed for risk assessment, provide a stable and foundational revenue stream for the company.
While the growth for these offerings is more measured, projected at 1-3% volume and revenue growth in Q2 2025, they command a significant market share. This strong market position allows them to generate consistent cash flow, requiring minimal additional investment to maintain their performance.
High Gross Margins from Lab Efficiencies
Myriad's commitment to operational excellence has translated into significant laboratory efficiencies, a key driver for its robust financial performance. This focus on streamlining processes allows the company to achieve impressive adjusted gross margins, which stood at 71.5% in the second quarter of 2025.
These high margins on its established product lines clearly demonstrate their status as cash cows. The company is effectively leveraging its operational strengths to generate substantial profits from these mature offerings, allowing it to maximize returns from existing investments.
BRACAnalysis and BRACAnalysis CDx
BRACAnalysis and BRACAnalysis CDx represent Myriad Genetics' established "cash cows" within the BCG matrix framework. These pioneering tests for hereditary cancer have carved out a significant market share, benefiting from strong brand recognition built over years of reliable performance.
While these products may be considered in a more mature stage, they consistently generate substantial and dependable cash flow for Myriad. This financial stability is crucial, underpinning the company's ability to invest in research and development for newer, potentially high-growth products.
- Market Leadership: BRACAnalysis was a first-of-its-kind test, establishing Myriad as a leader in hereditary cancer diagnostics.
- Consistent Revenue: These tests continue to be a primary revenue driver, contributing significantly to Myriad's financial health.
- Foundation of Business: They form the bedrock of Myriad's diagnostic portfolio, supporting innovation in other areas.
- Brand Loyalty: Decades of clinical use have fostered trust and loyalty among healthcare providers and patients.
Stable Revenue from Women's Health Segment
Myriad's Women's Health segment, encompassing prenatal and hereditary cancer tests for individuals without a current diagnosis, is a significant contributor to its financial stability. In the second quarter of 2025, this business unit generated an impressive $89.8 million in revenue.
This segment is characterized by its consistent performance and enduring demand, making it a dependable source of cash flow for Myriad. The predictable nature of these services underpins its classification as a Cash Cow within the BCG Matrix.
- Women's Health Revenue (Q2 2025): $89.8 million
- Key Offerings: Prenatal tests, hereditary cancer tests for unaffected individuals
- Performance Characteristic: Stable revenue and consistent demand
- BCG Matrix Classification: Cash Cow
Cash Cows: Stable Revenue Streams
Myriad's established hereditary cancer testing, particularly BRACAnalysis and BRACAnalysis CDx, are prime examples of Cash Cows. These pioneering tests have secured a dominant market share, fueled by decades of clinical use and strong brand recognition.
These mature offerings consistently generate substantial, dependable cash flow, which is crucial for funding Myriad's research and development in newer, high-growth areas. Their stable revenue stream, despite more measured growth projections, highlights their foundational importance to the company's financial health.
The Women's Health segment, including prenatal and hereditary cancer tests for unaffected individuals, also functions as a Cash Cow. This segment posted $89.8 million in revenue in Q2 2025, demonstrating stable performance and consistent demand.
The company's operational efficiencies, contributing to a 71.5% adjusted gross margin in Q2 2025, further bolster the profitability of these established product lines, solidifying their Cash Cow status.
| Product/Segment | BCG Classification | Q2 2025 Revenue | Projected Growth (2025) | Key Characteristic |
|---|---|---|---|---|
| BRACAnalysis/BRACAnalysis CDx | Cash Cow | N/A (Part of Women's Health) | 1-3% | Market leader, consistent cash flow |
| Prenatal Testing (Foresight, Prequel) | Cash Cow | N/A (Part of Women's Health) | N/A | Stable, resilient revenue driver |
| Women's Health (Overall) | Cash Cow | $89.8 million | N/A | Dependable, predictable cash flow |
What Youāre Viewing Is Included
Myriad BCG Matrix
The preview you're viewing is the identical, fully functional Myriad BCG Matrix document you'll receive upon purchase. This means no watermarks, no demo content, and no hidden surprises ā just the complete, professionally formatted strategic tool ready for immediate implementation. You can confidently assess its value and utility, knowing the purchased version will be exactly the same, enabling seamless integration into your business planning and decision-making processes.
